Genmab's revenue has rebased to a ~$1B quarterly run-rate after the 2024Q4 milestone spike, with 2026Q2 revenue up 24.9% YoY and gross margins holding at 92.7%. The company is transitioning to independent commercialization, evidenced by rising R&D and SG&A, bu...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue rebased to $1.2B in 2026Q2 (up 24.9% YoY) with gross margin at 92.7%, but operating margin volatility (35.2% in 2026Q2 vs. 25.1% in 2026Q1) reflects milestone timing and scaling costs.
Genmab is leveraging AI to accelerate drug discovery, optimize clinical trials, and bring new therapies to market faster.
The company's asset-light, royalty-driven model reduces risk and capital intensity while maintaining revenue streams.
The stock has been undervalued relative to pipeline potential, with 67% appreciation as the market recognized this gap.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.54+45.9% vs $0.37 | $1.2B+3.5% vs $1.1B |
Q2 2026 May 7, 2026 | $0.09-42.0% vs $0.15 | $896M-1.1% vs $906M |
Q1 2026 Feb 17, 2026 | $0.05-89.1% vs $0.46 | $1.1B-0.8% vs $1.1B |
Q4 2025 Nov 6, 2025 | $0.65+35.4% vs $0.48 | $1.0B+1.1% vs $1.0B |
Genmab A/S NASDAQ: GMAB expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company's vice president and head of investor relations.
Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $35.66 and last traded at $35.3850, with a volume of 234834 shares. The stock had previously closed at $35.22. Wall Street Analysts Forecast Growth GMAB has been the subject of
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Benchmark GMAB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Genmab A/S (GMAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.55 | $21.21B | 22.44 | -82.7% | 25.89% | 4.53% | — | |
| $734.81 | $75.7B | 17.71 | 0.99% | 27.86% | 18.49% | — | |
| $17.57 | $1.85B | -2.46 | 15.58% | -6.93% | -9.96% | — | |
| $117.14 | $23.74B | 18.27 | 21.22% | 27.71% | 29.7% | — | |
| $57.94 | $14.56B | 20.84 | 6.98% | 35.33% | 42.49% | — | |
| $106.94 | $12.68B | 41.77 | 37.55% | 24.86% | 180.63% | — |
Genmab A/S (GMAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GMAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Genmab A/S (GMAB) stock FAQ — growth, dividends, profitability & financials explained
Genmab A/S (GMAB) reported $4.13B in revenue for fiscal year 2025.
Genmab A/S (GMAB) saw revenue decline by 82.7% over the past year.
Yes, Genmab A/S (GMAB) is profitable, generating $788.1M in net income for fiscal year 2025 (25.9% net margin).
Genmab A/S (GMAB) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
Genmab A/S (GMAB) generated $867.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
